Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma

The combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) has significantly improved clinical outcomes in patients with advanced renal cell carcinoma (RCC). However, 40%-60% of patients still develop primary or acquired resistance. For those with resistant disease, current immune rechallenge strategies have yet to demonstrate clear clinical benefit. Emerging evidence indicates that the gut microbiota plays a critical role in modulating responses to immunotherapy. Microbiota-modulating approaches, including fecal microbiota transplantation (FMT) and live bacte

Trial Details

NCT ID
NCT07611825
Phase
PHASE2
Sponsor
Jinling Hospital, China
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • Toripalimab
  • Ipilimumab
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Pathological Diagnosis and Subtype Specification Histologically confirmed metastatic renal cell carcinoma (mRCC) of either clear cell type or non-c…
  • Based on the pathological subtype, enrolled patients will be assigned to two cohorts: the primary cohort consists of patients with histologically c…
  • Immunotherapy Resistance Patients must have received at least two cycles of PD-1/PD-L1 ICI therapy and demonstrated disease progression either duri…
  • Prior Treatment Lines and Sequence Restriction Patients must have received no more than two prior lines of systemic therapy, with no more than one …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →